Glycerin Laxative

Description

Glycerin is available in two dosage forms: 120-count and 60-count. It is a colorless, odorless, and viscous liquid that is hygroscopic in nature. Glycerin is commonly used as a humectant, solvent, and sweetening agent in various pharmaceutical and cosmetic formulations. Its molecular weight is 92.09 g/mol, and its chemical formula is C3H8O3.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 15 minutes to 1 hour of administration.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 6 years and older, the recommended dosage is one suppository per day, or as directed by a healthcare professional.

For children aged 2 to under 6 years, Neilmed Child Suppositories should be utilized. In the case of children under 2 years of age, it is advised to consult a doctor prior to administration.

The route of administration involves the insertion of one suppository well into the rectum. It is important to note that the suppository is formulated to dissolve only partially to achieve the desired laxative effect, which may not be visibly apparent.

Contraindications

Use of this product is contraindicated in patients who require laxative therapy for longer than one week without medical supervision. Prolonged use may lead to dependence or other adverse effects. It is essential to consult a healthcare professional for guidance on appropriate duration of use.

Warnings and Precautions

For rectal use only. In the event of accidental ingestion, it is imperative to seek medical assistance immediately or contact a Poison Control Center at 1-800-222-1222.

Laxative products should not be utilized for a duration exceeding one week unless specifically directed by a healthcare professional. Prolonged use may lead to dependency or other adverse effects.

Patients are advised to discontinue use and consult a physician if any of the following occur: rectal bleeding or failure to have a bowel movement after the administration of the laxative. These symptoms may indicate a serious underlying condition that requires further evaluation and intervention.

Side Effects

Patients should be aware that the product is intended for rectal use only. It is crucial to stop use and consult a healthcare professional if rectal bleeding occurs or if there is a failure to have a bowel movement after using the laxative, as these symptoms may indicate a serious underlying condition.

Before using this product, patients are advised to seek medical advice if they experience abdominal pain, nausea, or vomiting, or if they notice a sudden change in bowel habits that persists for more than two weeks. These precautions are important to ensure the safe and effective use of the product.

Drug Interactions

There are no specific drug interactions reported for this medication. Additionally, no laboratory test interactions have been identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Glycerin Laxative (glycerin laxative suppositories). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 years and older may be administered 1 suppository per day or as directed by a healthcare professional. For children aged 2 to under 6 years, Neilmed Child Suppositories are recommended. In infants and children under 2 years of age, consultation with a doctor is advised prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential implications of excessive dosing.

Recommended Actions

In the event of suspected overdosage, it is essential to monitor the patient closely for any adverse effects. Healthcare providers should initiate supportive care as necessary and consider contacting a poison control center for guidance on management strategies.

Potential Symptoms

While specific symptoms of overdosage are not detailed, healthcare professionals should remain vigilant for any unusual clinical manifestations that may arise following excessive administration of the medication.

Management Procedures

Management of overdosage should be tailored to the individual patient, taking into account their clinical status and any coexisting medical conditions. Supportive measures, including symptomatic treatment and monitoring of vital signs, are recommended until the patient stabilizes.

In summary, due to the lack of detailed overdosage information, healthcare professionals must rely on clinical judgment and established protocols for managing potential cases of overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to inform patients that laxative products should not be used for longer than one week unless directed by a physician.

Patients should be instructed to discontinue use and consult a doctor if they experience rectal bleeding or if they do not have a bowel movement after using the laxative, as these symptoms may indicate a serious underlying condition.

Additionally, healthcare providers should inform patients that the use of the product may result in rectal discomfort or a burning sensation. It is also essential to recommend that patients consult a doctor prior to use if they have abdominal pain, nausea, vomiting, or if they have noticed a sudden change in bowel habits lasting more than two weeks.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for reference. It is essential to store the product at room temperature, ensuring that the temperature does not exceed 30˚ C (86˚ F).

For tracking purposes, the Lot Number and Expiration Date can be found on the wrapper or box. Proper adherence to these storage conditions is crucial for maintaining the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Glycerin Laxative, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)